OTCMKTS:GNNSF Genscript Biotech (GNNSF) Stock Price, News & Analysis C$4.53 -0.97 (-17.64%) As of 10/13/2026 12:56 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartNews and Trends About Genscript Biotech Stock (OTCMKTS:GNNSF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Genscript Biotech alerts:Sign Up Key Stats Today's RangeC$4.40▼C$4.5550-Day RangeC$2.00▼C$6.3552-Week RangeC$1.30▼C$6.55Volume5,325 shsAverage Volume3,686 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview GenScript Biotech Corp. is a biotechnology company that provides research, development and manufacturing services to pharmaceutical, biotechnology and academic customers. Its offerings support work in molecular biology, drug discovery, cell and gene therapy, and other life science applications. The company’s life science services include gene synthesis, DNA and RNA products, oligonucleotides, peptides, recombinant proteins, antibodies, cell lines and related research reagents. GenScript also provides custom biological research, assay development and preclinical services designed to help customers advance candidates from early research toward clinical development. GenScript has expanded beyond research services into biologics and cell therapy development and manufacturing. Through its subsidiaries and affiliated businesses, the company has participated in the development of cell therapy products and provides contract development and manufacturing services for biopharmaceutical customers. Founded in 2002, GenScript serves customers internationally through operations and facilities in China, the United States, Europe and other regions.AI Generated. May Contain Errors. Read More Receive GNNSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genscript Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GNNSF Stock News HeadlinesAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Genscript Biotech (OtherGNNSF) and Cochlear (OtherCHEOF)August 21, 2026 | theglobeandmail.comGenscript Biotech Corporation (GNNSF) Q2 2026 Earnings Call TranscriptAugust 17, 2026 | seekingalpha.comA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe calls it The 10-Minute Guide to Start Trading Options Today, built to help you open your first options trade with less capital than buying shares outright. | True Market Insiders (Ad)Chinese biotech GenScript surges as it rebuffs US lawmakers’ allegationsJune 3, 2026 | msn.comGenScript Leaders Named Entrepreneur Of The Year(R) 2026 New Jersey FinalistsApril 24, 2026 | marketwatch.comGenScript Leaders Named Entrepreneur Of The Year® 2026 New Jersey FinalistsApril 23, 2026 | sg.finance.yahoo.comMimulus and GenScript Partner to Scale the World's First Zero-Watt Molecular Archive Infrastructure for the AI EraApril 10, 2026 | marketwatch.comGenScript reports strong fiscal 2025 results from platform strategyMarch 17, 2026 | msn.comSee More Headlines GNNSF Stock Analysis - Frequently Asked Questions How have GNNSF shares performed this year? Genscript Biotech's stock was trading at C$1.67 at the beginning of 2026. Since then, GNNSF stock has increased by 172.1% and is now trading at C$4.53. How do I buy shares of Genscript Biotech? Shares of GNNSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:GNNSF CIKN/A Webwww.genscript.com Phone862558897288FaxN/AEmployees6,165Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (OTCMKTS:GNNSF) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...Chaikin Analytics | SponsoredThis little-known gold fund distributes cash every FridayGold pays no dividends, no interest, no yield - it just sits there. Yet investors are reportedly collecting up...Investors Alley | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genscript Biotech Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genscript Biotech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.